56 results about "Targeted Radiotherapy" patented technology

Systems and methods for detecting and diagnosing faults in a radiotherapy system, such as a fault related to a dynamic leaf guide (DLG), are discussed. An exemplary predictive maintenance system includes a processor configured to receive machine data indicative of configuration and operation of a DLG in a target radiotherapy machine, apply a trained deep learning model to the received machine data, and detect and diagnose a DLG fault. The predictive maintenance system can train the deep learning model using data sequences constructed from the received machine data of the one more normal DLGs and the one or more faulty DLGs. Diagnosis of the DLG fault in the target radiotherapy machine includes classifying the DLG faults into different fault types or different fault severities.

The invention relates to the technical field of computers, and discloses an automatic segmentation and intelligent plan generation method and device suitable for self-adaptive radiotherapy of prostate cancer. Comprising the following steps: acquiring medical image data of a treated object, clinical dose data of a target area and an organ at risk in a focus area of the treated object, and clinical treatment data of a preset priority level; performing automatic segmentation based on the medical image data to obtain target segmentation data; performing dose distribution prediction according to the target segmentation data to obtain initial dose distribution data, and performing iterative optimization on the initial dose distribution data by using clinical treatment data to obtain target dose distribution data of the treated object; and performing iterative optimization of a radiotherapy plan based on the target dose distribution data, and generating a target radiotherapy plan of the treated object. Therefore, on the basis of realizing accurate, efficient and automatic segmentation of the prostate cancer target region and the endangered organ, multi-round iterative optimization of dose distribution and the radiotherapy plan is carried out, and finally a high-quality target radiotherapy plan is obtained.

The invention relates to a self-adaptive radiotherapy plan determination method, a self-adaptive radiotherapy system and a storage medium. The method comprises the following steps: acquiring a current region-of-interest segmentation result and current image features corresponding to a current image of an object; according to the segmentation result of the current region of interest and the current image features, candidate radiotherapy plans are selected from a plan library of the object, and the plan library comprises historical images of the object and corresponding historical radiotherapy plans; calculating a calculated dose distribution corresponding to the current image based on parameters in the candidate radiotherapy plan; determining the applicability of the candidate radiotherapy plan for the current image according to the calculated dose distribution, the segmentation result of the current region of interest and the features of the current image; and the target radiotherapy plan for the current image is determined based on the applicability, so that the generation efficiency and effectiveness of the adaptive radiotherapy plan are improved.

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenated phospholipid ether has the formula:wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein R1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.

Methods and kits for mitigating lung injury in a subject treated with a targeted radiation therapy or otherwise exposed to radiation are described. In particular, an effective amount of a thrombopoietin mimetic, such as RWJ-800088 or romiplostim, is used to mitigate the radiation-induced lung injury.

The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and / or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following:or a pharmaceutically acceptable salt thereof,or a pharmaceutically acceptable salt thereof,or a pharmaceutically acceptable salt thereof,wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.

This application discloses a real-time adaptive radiotherapy management system, relating to the field of medical technology. The system includes: a real-time data processing unit for acquiring real-time data of the target object during radiotherapy; an adaptive decision-making unit for determining a target radiotherapy plan matching the current state of the target object from multiple alternative radiotherapy plans based on the real-time data, wherein the multiple alternative radiotherapy plans are associated with different physiological motion phases or anatomical states of the target object; a plan execution sequence splitting unit for parsing and splitting each alternative radiotherapy plan into one or more hardware execution sequences; and an execution scheduling unit for sending at least one hardware execution sequence corresponding to the target radiotherapy plan to the control system of the radiotherapy equipment. This application solves the technical problem that existing adaptive radiotherapy systems, due to their rigid architecture and singular decision-making mode, cannot achieve highly real-time dynamic plan switching during treatment.

This invention discloses a folic acid receptor-targeting compound and its uses, belonging to the field of pharmaceutical technology. The folic acid receptor-targeting compound is a compound of formula (I), its stereoisomer, its crystalline hydrate, its deuterated derivative, its solvate, its prodrug, or a pharmaceutically acceptable salt thereof: [target]-(L x ) s -R x (I), where [target] is a folic acid receptor-binding ligand; R x The chelating group is Ch or the prosthetic group is PG; s is an integer from 1 to 10; L x It contains at least one L 3 and with AA, L 1 L 2 or L 3 Arbitrary combinations are possible. The folic acid receptor-targeting compounds of this invention have low KD values ​​and strong affinity between the ligands and receptors, and can be used as folic acid receptor-targeted radiotherapy agents for imaging, diagnosis, and treatment of folic acid receptor (FR)-expressing tumors or cells.

The disclosed method of treating a malignant solid tumor in a subject comprises the steps of administering to the subject an immunomodulatory dose of a radiophosphatide ether metal chelate, a radiohalogenated phosphatide ether, or other targeted radiotherapy (TRT) agent differentially retained in the malignant solid tumor, and treating the malignant solid tumor by systemically administering an immunostimulatory agent to the subject. Immunotherapy is performed in a subject, such as an immune checkpoint inhibitor. In a non-limiting example, a radioactive phospholipid ether metal chelate or radioactive halogenated phospholipid ether has the formula: # imgabs0 # wherein R1 comprises a chelating agent that chelates with a metal atom wherein the metal atom is an alpha, beta or Auger emitting metal isotope having a half-life of greater than 6 hours and less than 30 days, or wherein R1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is-N + (CH3) 3.

The invention relates to an isocenter optimization selection method for a radiotherapy target plan, and the method comprises the steps: obtaining a CT image, and carrying out the preprocessing of the CT image, and obtaining an initial Mask matrix; based on the initial Mask matrix, calculating to obtain a rotated Mask matrix; establishing and searching an optimal plan center point loss function; and based on a random optimization algorithm, solving to obtain an optimal plan center point. Compared with the prior art, the method has the advantages that potential geometric errors caused by rotation uncertainty in the actual treatment process can be reduced, the optimal isocenter point is determined, and the target coverage rate and the coverage precision are improved.

Disclosed herein is an engineered bacterium comprising a chimeric nucleic acid comprising: a first nucleic acid encoding an ompA protein or a fragment thereof; and a second nucleic acid encoding a radiohapten binding protein. Further disclosed are methods of using these constructs in methods for pre-targeted radiotherapy and for treating tumors.

Disclosed herein are compounds, combinations, and kits that can be used to more quickly remove radionuclides from a subject, preferably a human being. Said compounds, combinations and kits can also be used to increase the tumor-to-blood ratio, or to more rapidly and / or conveniently achieve such an increase, of a label in targeted imaging or targeted radiotherapy in a subject, preferably a human being.

The present invention relates to a core / shell radioactive nanoparticle comprising: - a core based on a porous material, comprising one or more α-emitting radionuclide(s), - a first intermediate shell around the core, - optionally a second intermediate shell located between the first intermediate shell and the outer shell, and - an outer shell. The present invention also relates to the use of this radioactive nanoparticle as a drug, in particular in the prevention and / or treatment of cancer, and / or as an imaging agent.

A pharmacological composition contains a complex having a structurally modified RGD polypeptide a radionuclide. This pharmacological composition is useful for diagnosis or treatment of the integrin αvβ3-positive tumors. The pharmacological composition may further contain an immunotherapeutic medicament and an optional nanoantibody molecular imaging probe. Treatment with a PD-L1 blockade after the targeted radioactive therapy can archive the optimal synergic efficacy. Moreover, with administration of PD-1 or PD-L1 nanoantibody molecular imaging probe, expression of PD-1 or PD-L1 in the tumor after targeted radiotherapy can be observed.

The present invention relates to a tetrapeptide binding to the cholecystokinin 2 receptor (CCK-2R) wherein the tetrapeptide is represented by the formula (I) Xaa1-Xaa2-Xaa3-Xaa4 (formula (I)) or a salt thereof wherein Xaa1 is Trp, (beta-(3-benzothienyl)-alanine, Trp wherein one or more H atoms of 1H-indol-3-yl are substituted with substituents, and wherein one or more H atoms of the 1H-indol-3-yl are substituted with substituents, and X is a hydrogen atom or a hydrogen atom of the (beta-(3-benzothienyl)-alanine. Wherein, for each H atom, the substituents are independently selected from C1 to C3 alkyl,-OH,-SH,-F and-Cl, Phe, 1-Nal, 2-Nal, Tyr or para-amino-Phe, Xaa2 is an N-methylamino acid wherein N-methyl is at a carbon alpha, and preferably an N-methylamino acid containing an aliphatic side chain wherein N-methyl is at a carbon alpha, Xaa3 is an amino acid having an acidic side chain at neutral pH, and X is an amino acid having an aliphatic side chain at neutral pH. And Xaa4 is an amino acid having an aromatic side chain or an amide thereof.

The invention provides a close-range radiotherapy template printing data determination method. According to the method, medical image data of a to-be-detected area of a target object is acquired, an original radiotherapy template three-dimensional model is generated according to the medical image data, and then a receptor area and a diffusion area on a source application curved surface are determined according to the receptor curved surface of target tissue in the to-be-detected area; a needle insertion channel set is generated in the original radiotherapy template three-dimensional model, and target radiotherapy template printing data is generated according to the original radiotherapy template three-dimensional model and the needle insertion channel set; therefore, the radiotherapy template formed after the determined radiotherapy template printing data is subjected to three-dimensional printing can utilize the receptor area to realize comprehensive coverage of the current tumor tissue, and can also utilize the diffusion area to realize prediction matching of tumor tissue edge development. The complex process of repeatedly sampling medical images and manufacturing radiotherapy templates is effectively avoided.

The present application discloses an error determination method, device and electronic device for an accelerator, and relates to the field of medical technology. The method includes: obtaining a preset plan and a target radiotherapy plan for a target object, wherein the preset plan is used to test the accelerator device through pre-set accelerator device parameters; executing the preset plan on the accelerator device to obtain the target execution result of the accelerator device for the preset plan; determining the target error of the accelerator device according to the target execution result; determining the estimated dose information according to the target error, wherein the estimated dose information represents the dose information generated by the accelerator device when executing the target radiotherapy plan in the presence of a target error. The present application solves the technical problem in the prior art that the device status of the accelerator cannot be verified before the treatment of each patient, resulting in poor controllability of the radiotherapy effect for the patient.

Example methods and systems for deep transfer learning for radiotherapy treatment planning are provided. One example method may comprise: obtaining (310) a base deep learning engine that is pre-trained to perform a base radiotherapy treatment planning task; and based on the base deep learning engine, generating a target deep learning engine to perform a target radiotherapy treatment planning task. The target deep learning engine may be generated by configuring (330) a variable base layer among multiple base layers of the base deep learning engine, and generating (340) one of multiple target layers of the target deep learning engine by modifying the variable base layer. Alternatively or additionally, the target deep learning engine may be generated by configuring (350) an invariable base layer among the multiple base layers, and generating (360) one of multiple target layers of the target deep learning engine based on feature data generated using the invariable base layer.

To provide macrocyclic complex-containing compositions comprising radionuclides that are less toxic to non-targeted tissue and useful for targeted radiotherapy of cancer.SOLUTION: Provided herein are compositions comprising compounds represented by the formula in the figure or pharmaceutically acceptable salts thereof. In the formula, M is an α-emitting radionuclide.SELECTED DRAWING: None

The present invention relates to compounds of formula (I) that have the ability to be used as metal complexes in radiotherapy.whereinA is selected from the group consisting of CO2R1, and PO3R1;B is selected from the group consisting of CO2R2, and PO3R2;R1, R2 and R3 are each independently selected from the group consisting of H and C1-C12alkyl;each Ra is independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN;each Rb is independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN;L is a linker having from 1 to 20 atoms in the normal chain;or a pharmaceutically acceptable salt thereof.

The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and / or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following:or a pharmaceutically acceptable salt thereof,or a pharmaceutically acceptable salt thereof,or a pharmaceutically acceptable salt thereof,wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.

The present invention relates to compounds of formula (I) that have the potential to be used as metal complexes in radiotherapy. TIFF2024538619000043.tif85132 (wherein A is CO2R 1 , and PO3R 1 and B is selected from the group consisting of COR 2 , and PO3R 2 R 1 , R 2 and R 3 are each independently H and C1 to C 12 alkyl, and each R a is independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN; b are independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN, and L is a linker having 1 to 20 atoms in the normal chain), or a pharma- ceutically acceptable salt thereof.

The present invention relates to a radioactive nanoparticle of core / shell type comprising: - a porous silica-based core comprising one or more α-emitting radionuclide(s) and one or more β-emitting radionuclide(s), and - a metal shell. The present invention also relates to the use of this radioactive nanoparticle as a medicament, in particular in the prevention and / or treatment of cancer, and / or as an imaging agent.

The invention relates to the field of medical instruments, in particular to a nasal esophageal tracheal fistula three-balloon nasal feeding tube composite set loaded with radioactive particles, which comprises a tube body, a lower blocking balloon, a particle balloon, an upper blocking balloon, a tube body butt joint structure and a nasal guide structure. The radion-loaded three-balloon nasal feeding tube composite set for the nasal esophageal and tracheal fistula is a medical instrument which is combined with the nasal feeding tube and can be used for blocking and treating a fistula opening of a patient suffering from the esophageal and esophageal fistula and carrying out precise targeted radiotherapy on cancerous parts of esophageal cancer, and diet nutrition conveying of the patient is facilitated. The device is simple in structure, convenient to operate, high in working and operating efficiency, stable in operation, beneficial to popularization and promotion, capable of effectively relieving pain of patients, convenient to mount and dismount, obvious in acting effect, capable of achieving differentiated treatment, stable in whole and high in pertinence, and has wide market prospects.

The present invention provides a radiotherapy dose warning method, comprising receiving target radiotherapy plan data corresponding to a target patient and target CBCT data of the target patient during each radiotherapy; calculating the target density variable of the CBCT data of the target patient during each radiotherapy according to the target reflection therapy plan data and the target CBCT data; outputting each of the target density variables to a preset dose characteristic solution model to obtain the corresponding target radiation source dose characteristic; judging whether the target radiation source dose characteristic is within the clinical dose characteristic standard range, and if not, issuing a warning message. A radiotherapy dose warning method of the present invention does not require complex calculations of the target radiation source dose characteristic, simplifies the preliminary calculation process of the radiotherapy dose warning, and improves the efficiency of the warning.

The utility model relates to the field of medical instruments, in particular to a nasal esophageal tracheal fistula three-balloon nasal feeding tube composite set loaded with radioactive particles, which comprises a tube body, a lower blocking balloon, a particle balloon, an upper blocking balloon, a tube body butt joint structure and a nasal guide structure. The radion-loaded three-balloon nasal feeding tube composite set for the nasal esophageal and tracheal fistula is a medical instrument which is combined with the nasal feeding tube and can be used for blocking and treating a fistula opening of a patient suffering from the esophageal and esophageal fistula and carrying out precise targeted radiotherapy on a cancerous part of esophageal cancer, and feeding nutrition of the patient is convenient to convey. The device is simple in structure, convenient to operate, high in working and operating efficiency, stable in operation, beneficial to popularization and promotion, capable of effectively relieving pain of patients, convenient to mount and dismount, obvious in acting effect, capable of achieving differentiated treatment, stable in whole and high in pertinence, and has wide market prospects.

The invention discloses application of APOL2 protein or a coding gene thereof as a target spot in preparation of anti-gastric cancer drugs. Researches prove that the expression of the APOL2 protein in human gastric cancer tissues is obviously higher than that in normal gastric tissues and is related to poor prognosis. After radiotherapy, overexpression of APOL2 can promote growth of tumors. The rising of the APOL2 protein level can be used as a biomarker for diagnosis and prognosis of gastric cancer; the APOL2 can be used as a novel molecular target for radiotherapy targeted therapy of gastric cancer.

The present invention relates to an inhibitor targeting platelet-derived growth factor receptor β (PDGFRβ), a radioactive probe and their applications, belonging to the fields of nuclear medicine imaging agents and radionuclide radiotherapy agents. The inhibitor of the present invention is at least one of the compounds shown by formula I, and the radioactive probe is at least one of the compounds shown by formula II. The radioactive probe targeting PDGFRβ provided by the present invention can specifically target tumors with high expression of PDGFRβ, and has good tumor uptake and rapid in vivo metabolism properties. The radioactive probe targeting PDGFRβ provided by the present invention has a good tumor-to-background ratio, can be rapidly metabolized and excreted from the body through the kidneys, and has important clinical application value for the early and accurate diagnosis and targeted radiotherapy of PDGFRβ-positive tumors and screening of beneficiaries of anti-angiogenic treatment strategies.

The invention discloses a real-time adaptive radiotherapy management system, and relates to the field of medical science and technology. The system comprises a real-time data processing unit used for acquiring real-time data of a target object in a radiotherapy process; the self-adaptive decision-making unit is used for determining a target radiotherapy plan matched with the current state of the target object from multiple alternative radiotherapy plans of the target object based on the real-time data, and the multiple alternative radiotherapy plans are associated with different physiological motion phases or anatomical states of the target object; the plan execution sequence splitting unit is used for analyzing and splitting each alternative radiotherapy plan into one or more hardware execution sequences; and the execution scheduling unit is used for issuing the at least one hardware execution sequence corresponding to the target radiotherapy plan to a control system of the radiotherapy equipment. The technical problem that an existing adaptive radiotherapy system cannot realize high-real-time dynamic plan switching in the treatment process due to framework stiffness and single decision mode is solved.

Provided herein are methods for treating cancer, including pancreatic cancer, lung cancer, or breast cancer, comprising administering to a subject in need thereof a FAP-targeted radiotherapeutic as a monotherapy or in combination with one or more chemotherapeutic agents.